Headlines about AxoGen (NASDAQ:AXGN) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AxoGen earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.6531074358754 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities research analysts recently commented on the company. William Blair assumed coverage on AxoGen in a research report on Monday. They issued an “outperform” rating on the stock. Leerink Swann boosted their target price on AxoGen from $23.00 to $26.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Cantor Fitzgerald set a $37.00 target price on AxoGen and gave the stock a “buy” rating in a research report on Monday, January 8th. Wedbush reiterated a “buy” rating and issued a $27.00 target price (up from $22.00) on shares of AxoGen in a research report on Tuesday, November 21st. Finally, Lake Street Capital boosted their target price on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 21st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. AxoGen currently has an average rating of “Buy” and a consensus price target of $29.33.
Shares of AxoGen (AXGN) opened at $26.65 on Monday. AxoGen has a 52-week low of $9.55 and a 52-week high of $31.70. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. The stock has a market capitalization of $908.60, a P/E ratio of -63.45 and a beta of 0.60.
In other AxoGen news, Director Guido J. Neels sold 1,150,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $19.74, for a total transaction of $22,701,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jamie Mark Grooms sold 21,290 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $26.22, for a total value of $558,223.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,293,990 shares of company stock worth $26,494,898. Company insiders own 9.33% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.